In lung cancers and PCs, SMYD3 has a pivotal role in the regulation of oncogenic RAS signaling through the methylation of MAP3K2 kinase on lysine 206, which induces MAP3K2 release from the negative regulator PP2A phosphatase complex and therefore promotes ERK1/2 phosphoactivation [15]. The gene discussed is SMYD3; the disease is lung cancer.